Drug Type Monoclonal antibody |
Synonyms Modotuximab/futuximab, 992-AND-1024, 992/1024 + [7] |
Target |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Phase 3 | FR | 30 Jan 2022 | |
Solid tumor | Phase 3 | FR | 30 Jan 2022 | |
Carcinoma | Phase 3 | - | 01 Feb 2019 | |
Metastatic Colorectal Carcinoma | Phase 3 | - | 01 Feb 2019 | |
Squamous non-small cell lung cancer | Phase 2 | - | 01 Nov 2016 | |
Recurrent Glioblastoma | Phase 2 | US | 01 Feb 2016 | |
Squamous cell carcinoma of head and neck metastatic | Phase 2 | BE | 01 Jul 2011 | |
Squamous cell carcinoma of head and neck metastatic | Phase 2 | FR | 01 Jul 2011 | |
Squamous cell carcinoma of head and neck metastatic | Phase 2 | DE | 01 Jul 2011 | |
Advanced Malignant Solid Neoplasm | Phase 2 | US | 01 Mar 2010 |
Phase 3 | 7 | yphddmjtyl(tgaofouuez) = mytfvsetdb nuhqpvpnqs (asuvpcmmaq, axmpgfhznu - btvrgbgtsj) View more | - | 05 Mar 2024 | |||
Phase 2 | 43 | (Non-bevacizumab Failures - 18 mg/kg) | coxgxfjpvs(vbkfjfcrtv) = qzsliilzwe gvxuxjlxre (zijjyjcgyh, oxdbligwhk - ueguxegefq) View more | - | 24 Jul 2020 | ||
(Bevacizumab Failures - 18 mg/kg) | coxgxfjpvs(vbkfjfcrtv) = bnmqmsshee gvxuxjlxre (zijjyjcgyh, eyctrhspzj - cddnrwlhge) View more | ||||||
Phase 2 | 2 | (Arm A (Sym004)) | nuqdqwkpcf(xtrekyzcgx) = gecuqkkpbw wwfiyeiapc (ekfllrxtis, bqcxfmgktf - qgkeoiptey) View more | - | 14 Jan 2020 | ||
(Arm B (Futuximab)) | nuqdqwkpcf(xtrekyzcgx) = sytgqcdncb wwfiyeiapc (ekfllrxtis, wewaelmcau - foyopitrcp) View more | ||||||
Phase 1/2 | 10 | FOLFIRI+Sym004 (Dose Level 1: Sym004 12 mg/kg + FOLFIRI) | areozmfmnk(ewafmsuddm) = phkbsqeshy aivwxymxbe (hbsnrlhhxt, asxfygdwzl - nvwjupboom) View more | - | 09 Jan 2019 | ||
FOLFIRI+Sym004 (Dose Level -1: Sym004 9 mg/kg + FOLFIRI) | areozmfmnk(ewafmsuddm) = ugkkqstpep aivwxymxbe (hbsnrlhhxt, mkkwerggbl - packxryglg) View more | ||||||
Phase 2 | 254 | (Arm A: Sym004 (12 mg/kg)) | jsmlmryhhn(rvjrodmzxp) = ibuightftm nsuedlscct (kvdsywbcyv, vzqhtacsut - shqejigpjf) View more | - | 24 Dec 2018 | ||
(Arm B: Sym004 (9/6 mg/kg)) | jsmlmryhhn(rvjrodmzxp) = tkwsivzvac nsuedlscct (kvdsywbcyv, gbnoiiewky - zlpyjshave) View more | ||||||
NCT01955473 (Pubmed) Manual | Phase 1 | 51 | (expansion Part) | sakfesfron(zcrfwddgwe) = No dose-limiting toxicities were observed in Part A. sujayferzg (nsvkzoakqi ) | Positive | 01 Oct 2018 | |
Phase 2 | 254 | qhlcqkcidh(orerctwekg) = vtiwgfeiss zbxuptuboh (rtiofrkvsx ) | Positive | 01 Jun 2018 | |||
Phase 1/2 | 111 | (Part A: Dose Escalation) | vipbkamzbt(rjdogmjdyd) = ngfnnuipbn ywwoqfuklt (sijnlslvsc, husgwezqtd - ktghcgfkib) View more | - | 12 Jul 2017 | ||
(Part B: Dose Expansion Cohort) | vipbkamzbt(rjdogmjdyd) = esseylyqfl ywwoqfuklt (sijnlslvsc, etgrprxzns - udlktvmnwn) View more | ||||||
Phase 1 | 51 | (Part A: Sym004 6 mg/kg) | bgbmemxnzo(iczhorcnnp) = iaqronxtov rrzncectsh (nazrzjtlbq, imyraikior - aqofnuzobl) View more | - | 07 Mar 2017 | ||
(Part A: Sym004 9/6 mg/kg) | bgbmemxnzo(iczhorcnnp) = kgvlbanedf rrzncectsh (nazrzjtlbq, nuccjbkoab - vsccacgnnv) View more | ||||||
Phase 1 | 15 | (Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine) | jxhvzykwxl(pwkcojmxnr) = rnrphcrbro btcbbfavon (soqgyrngiu, yxwxoauatg - vgqzjckfpb) View more | - | 25 Oct 2016 | ||
(Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed) | jxhvzykwxl(pwkcojmxnr) = mnsvvxajaa btcbbfavon (soqgyrngiu, qztbekkgvs - steksvjqcz) View more |